09:53 AM EST - Acerus Pharmaceuticals Corporation : Reported its financial results for the three month period ended March 31, 2016 and provided a business update. Unless otherwise noted, all amounts are in U.S. dollars. Revenues for first quarter 2016 totaled $10.4 million (compared to $3.2 million for first quarter 2015). Earnings before interest, tax, depreciation and amortization (“EBITDA”) for first quarter 2016 was a loss of $1.5 million compared to a profit of $0.9 million in first quarter 2015. Acerus Pharmaceuticals Corporation
shares T.ASP are trading down $0.005 at $0.16.
